New Directions in Monoclonal Antibodies: Technologies, Markets, CompetitionCHI Insight Pharma ReportsOctober 1, 2004 185 Pages - SKU: CHI1080692 |
This report examines the more than 110 mAb products currently in clinical trials, as well as the products that are already available and those still at the preclinical stage that are likely to play an important role in the advancement of the field. The report presents further analysis to evaluate the market potential for monoclonal antibodies in development for a variety of diseases. It reviews some general observations concerning commercialization of mAbs, then addresses the major disease categories, including patient numbers for diseases of interest; competing therapeutics already on the market, particularly those that have recently gained regulatory approval; and, where available, estimates of market sizes in dollars. Only those conditions for which drug candidates have been identified or which have been prominently mentioned as potential markets by pharmaceutical companies in the field are covered. Please Note: The cost of Instant Online Delivery for this report also includes a country license - this means that any of an organization's branches within the same country can access the data without an additional fee. |
Related Markets
Antibody Technologies Reports
- Triple Analysis: Protein Kinase Inhibitors, Antibodies and Peptides
- Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies